The results of the Phase 1 clinical trial, published in an international journal, indicate that the Argentine ARVAC CG vaccine against COVID-19 is safe and immunogenic.
Argentine ARVAC Cecilia Grierson’s (ARVAC CG) vaccine against COVID-19 is safe and triggers a strong immune response against the Ancestral, Gamma, delta and Ómicron variants of SARS-CoV-2. This is revealed …